SLC5A2 and chronic kidney disease: SGLT2 inhibitors and GLP‐RAs may be beneficial in this cohort of patients due to their multi‐faceted actions in improving several outcomes such as weight loss, glycemic control, progression of CKD, cardiovascular events and all‐cause mortality.140